View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAcuCort 과거 순이익 실적과거 기준 점검 0/6AcuCort 의 수입은 연평균 -20%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 8.5%의 비율로 증가했습니다. 매출은 연평균 26%의 비율로 증가해 왔습니다.핵심 정보-19.98%순이익 성장률17.30%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률25.96%자기자본이익률-38.20%순이익률-312.21%다음 순이익 업데이트20 Feb 2026최근 과거 실적 업데이트공고 • Jan 22AcuCort AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026AcuCort AB (publ) announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on Feb 20, 2026Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr2.37m (up 36% from 3Q 2024). Net loss: kr5.34m (loss widened 115% from 3Q 2024).공고 • Oct 16AcuCort AB (publ) to Report Q3, 2025 Results on Nov 14, 2025AcuCort AB (publ) announced that they will report Q3, 2025 results on Nov 14, 2025Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr1.34m (up 5.3% from 2Q 2024). Net loss: kr7.57m (loss widened 99% from 2Q 2024).공고 • Jul 21AcuCort AB (publ) to Report Q2, 2025 Results on Aug 19, 2025AcuCort AB (publ) announced that they will report Q2, 2025 results on Aug 19, 2025Reported Earnings • Apr 20Full year 2024 earnings releasedFull year 2024 results: Revenue: kr7.72m (up 17% from FY 2023). Net loss: kr17.4m (loss widened 27% from FY 2023).모든 업데이트 보기Recent updates공고 • Jan 22AcuCort AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026AcuCort AB (publ) announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on Feb 20, 2026분석 기사 • Dec 03AcuCort (BST:NV5) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr2.37m (up 36% from 3Q 2024). Net loss: kr5.34m (loss widened 115% from 3Q 2024).공고 • Oct 16AcuCort AB (publ) to Report Q3, 2025 Results on Nov 14, 2025AcuCort AB (publ) announced that they will report Q3, 2025 results on Nov 14, 2025공고 • Oct 15AcuCort Appoints Anna Chérouvrier Hansson as Business Development DirectorAcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets.Anna Chérouvrier Hansson brings more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus.At SenzaGen, she played a key role in building and driving the company's business development and commercialisation strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in the launch of the company's first commercial product in supportive cancer care across several international markets.Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr1.34m (up 5.3% from 2Q 2024). Net loss: kr7.57m (loss widened 99% from 2Q 2024).분석 기사 • Aug 16We're Hopeful That AcuCort (BST:NV5) Will Use Its Cash WiselyBST:NV5 1 Year Share Price vs Fair Value Explore AcuCort's Fair Values from the Community and select yours There's no...공고 • Jul 21AcuCort AB (publ) to Report Q2, 2025 Results on Aug 19, 2025AcuCort AB (publ) announced that they will report Q2, 2025 results on Aug 19, 2025Reported Earnings • Apr 20Full year 2024 earnings releasedFull year 2024 results: Revenue: kr7.72m (up 17% from FY 2023). Net loss: kr17.4m (loss widened 27% from FY 2023).공고 • Apr 09AcuCort AB (publ) to Report Q1, 2025 Results on May 08, 2025AcuCort AB (publ) announced that they will report Q1, 2025 results on May 08, 2025공고 • Mar 20AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in NorwayAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit® from the Norwegian Medical Products Agency (Direktoratet for medisinske produkter), Norway's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit® in Norway in 2022. That approval was time-limited, which is standard for new medicines. Following an application for renewal, the Norwegian Medical Products Agency has now granted an extended marketing authorisation for the Norwegian market, this time without a time restriction.공고 • Mar 19AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in DenmarkAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit from the Danish Medicines Agency (Laegemiddelstyrelsen), Denmark's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit in Denmark in 2022. That approval was time-limited, which is standard for new medicines. Now, following an inspection by the Swedish Medical Products Agency, the Danish Medicines Agency has granted an extended marketing authorisation, this time without a time limitation.공고 • Mar 05AcuCort AB (publ) Receives Renewed Marketing Authorisation from the Swedish Medical Products AgencyAcuCort AB (publ) has received renewed marketing authorisation for its medicinal product Zeqmelit® from the Swedish Medical Products Agency. The decision is valid indefinitely. AcuCort applied for and was granted marketing authorization for its medicinal product in 2020. That authorization was valid for a period of five years, which is standard practice for new medicines. As a result, AcuCort applied for an extension, and the Swedish Medical Products Agency has now granted renewed marketing authorisation, effective from 6 October 2025. This time, the authorisation is valid without time limitation.공고 • Jan 23AcuCort AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025AcuCort AB (publ) announced that they will report fiscal year 2024 results on Feb 21, 2025New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$629k). Market cap is less than US$10m (€6.94m market cap, or US$7.14m).Reported Earnings • Dec 04Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr1.74m (up 1.2% from 3Q 2023). Net loss: kr2.48m (loss narrowed 21% from 3Q 2023).New Risk • Nov 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr25m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (281% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$642k). Market cap is less than US$10m (€7.40m market cap, or US$7.83m).공고 • Nov 14All Patients Completed AcuCort's Phase IV Study ZEQ001AcuCort's Phase IV study, ZEQ001, began in late January 2024. This study enrolled 50 patients, and the last participant has now completed it. The study findings are intended to be published in scientific journals, providing key support for AcuCort's upcoming launch initiatives. A key objective of the study, an open, non-randomised, low-intervention study, is to obtain scientific data from patients who previously used tablets but, in the study, are using Zeqmelit® instead. The study will answer essential questions, such as whether patients feel confident with Zeqmelit®, what the experience of using the medication is like, and whether they carry it with them. The study results will be published in scientific journals, thereby providing crucial support for the launch of Zeqmelit® in selected markets.공고 • Oct 24AcuCort AB (publ) to Report Q3, 2024 Results on Nov 22, 2024AcuCort AB (publ) announced that they will report Q3, 2024 results on Nov 22, 2024공고 • Sep 03Acucort AB (Publ) Announces Launch of Zeqmelit®? Initiated - Now Available At PharmaciesAcuCort has previously announced that the market launch of Zeqmelit®? would begin in early September. In line with this plan, Zeqmelit®? is available at Swedish pharmacies starting on September 2nd. The product will soon also be available at pharmacies in Norway and Finland. The launch is proceeding exactly as planned, and have thus achieved yet another important milestone. Physicians can prescribe Zeqmelit®?, and the product is now available at Swedish pharmacies. It will soon also be available at hospitals in Norway and Finland.공고 • Jul 25AcuCort AB (publ) to Report First Half, 2024 Results on Aug 23, 2024AcuCort AB (publ) announced that they will report first half, 2024 results on Aug 23, 2024Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Monica Wallter was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Oct 12AcuCort AB (publ) to Report Q3, 2023 Results on Nov 10, 2023AcuCort AB (publ) announced that they will report Q3, 2023 results on Nov 10, 2023공고 • Jul 13AcuCort AB (publ) to Report Q2, 2023 Results on Aug 11, 2023AcuCort AB (publ) announced that they will report Q2, 2023 results on Aug 11, 2023매출 및 비용 세부 내역AcuCort가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:NV5 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비30 Sep 259-275030 Jun 258-246031 Mar 258-205031 Dec 248-175030 Sep 247-145030 Jun 247-155031 Mar 247-145031 Dec 237-145030 Sep 236-13-6030 Jun 235-145031 Mar 235-154031 Dec 225-154030 Sep 225-1414030 Jun 225-133031 Mar 224-133031 Dec 213-113030 Sep 211-103030 Jun 211-93031 Mar 211-82031 Dec 202-82030 Sep 206-8-2030 Jun 205-90031 Mar 205-92031 Dec 194-83030 Sep 190-88030 Jun 190-66031 Mar 190-66031 Dec 180-66030 Sep 180-55030 Jun 180-55031 Mar 180-55031 Dec 170-55030 Sep 170-55030 Jun 170-44031 Mar 170-33031 Dec 160-220양질의 수익: NV5 은(는) 현재 수익성이 없습니다.이익 마진 증가: NV5는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: NV5은 수익성이 없으며 지난 5년 동안 손실이 연평균 20% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 NV5의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: NV5은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(16.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: NV5는 현재 수익성이 없으므로 자본 수익률이 음수(-38.2%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/12 21:50종가2026/02/09 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AcuCort AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Jan 22AcuCort AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026AcuCort AB (publ) announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on Feb 20, 2026
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr2.37m (up 36% from 3Q 2024). Net loss: kr5.34m (loss widened 115% from 3Q 2024).
공고 • Oct 16AcuCort AB (publ) to Report Q3, 2025 Results on Nov 14, 2025AcuCort AB (publ) announced that they will report Q3, 2025 results on Nov 14, 2025
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr1.34m (up 5.3% from 2Q 2024). Net loss: kr7.57m (loss widened 99% from 2Q 2024).
공고 • Jul 21AcuCort AB (publ) to Report Q2, 2025 Results on Aug 19, 2025AcuCort AB (publ) announced that they will report Q2, 2025 results on Aug 19, 2025
Reported Earnings • Apr 20Full year 2024 earnings releasedFull year 2024 results: Revenue: kr7.72m (up 17% from FY 2023). Net loss: kr17.4m (loss widened 27% from FY 2023).
공고 • Jan 22AcuCort AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026AcuCort AB (publ) announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on Feb 20, 2026
분석 기사 • Dec 03AcuCort (BST:NV5) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr2.37m (up 36% from 3Q 2024). Net loss: kr5.34m (loss widened 115% from 3Q 2024).
공고 • Oct 16AcuCort AB (publ) to Report Q3, 2025 Results on Nov 14, 2025AcuCort AB (publ) announced that they will report Q3, 2025 results on Nov 14, 2025
공고 • Oct 15AcuCort Appoints Anna Chérouvrier Hansson as Business Development DirectorAcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets.Anna Chérouvrier Hansson brings more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus.At SenzaGen, she played a key role in building and driving the company's business development and commercialisation strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in the launch of the company's first commercial product in supportive cancer care across several international markets.
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr1.34m (up 5.3% from 2Q 2024). Net loss: kr7.57m (loss widened 99% from 2Q 2024).
분석 기사 • Aug 16We're Hopeful That AcuCort (BST:NV5) Will Use Its Cash WiselyBST:NV5 1 Year Share Price vs Fair Value Explore AcuCort's Fair Values from the Community and select yours There's no...
공고 • Jul 21AcuCort AB (publ) to Report Q2, 2025 Results on Aug 19, 2025AcuCort AB (publ) announced that they will report Q2, 2025 results on Aug 19, 2025
Reported Earnings • Apr 20Full year 2024 earnings releasedFull year 2024 results: Revenue: kr7.72m (up 17% from FY 2023). Net loss: kr17.4m (loss widened 27% from FY 2023).
공고 • Apr 09AcuCort AB (publ) to Report Q1, 2025 Results on May 08, 2025AcuCort AB (publ) announced that they will report Q1, 2025 results on May 08, 2025
공고 • Mar 20AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in NorwayAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit® from the Norwegian Medical Products Agency (Direktoratet for medisinske produkter), Norway's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit® in Norway in 2022. That approval was time-limited, which is standard for new medicines. Following an application for renewal, the Norwegian Medical Products Agency has now granted an extended marketing authorisation for the Norwegian market, this time without a time restriction.
공고 • Mar 19AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in DenmarkAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit from the Danish Medicines Agency (Laegemiddelstyrelsen), Denmark's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit in Denmark in 2022. That approval was time-limited, which is standard for new medicines. Now, following an inspection by the Swedish Medical Products Agency, the Danish Medicines Agency has granted an extended marketing authorisation, this time without a time limitation.
공고 • Mar 05AcuCort AB (publ) Receives Renewed Marketing Authorisation from the Swedish Medical Products AgencyAcuCort AB (publ) has received renewed marketing authorisation for its medicinal product Zeqmelit® from the Swedish Medical Products Agency. The decision is valid indefinitely. AcuCort applied for and was granted marketing authorization for its medicinal product in 2020. That authorization was valid for a period of five years, which is standard practice for new medicines. As a result, AcuCort applied for an extension, and the Swedish Medical Products Agency has now granted renewed marketing authorisation, effective from 6 October 2025. This time, the authorisation is valid without time limitation.
공고 • Jan 23AcuCort AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025AcuCort AB (publ) announced that they will report fiscal year 2024 results on Feb 21, 2025
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$629k). Market cap is less than US$10m (€6.94m market cap, or US$7.14m).
Reported Earnings • Dec 04Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr1.74m (up 1.2% from 3Q 2023). Net loss: kr2.48m (loss narrowed 21% from 3Q 2023).
New Risk • Nov 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr25m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (281% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$642k). Market cap is less than US$10m (€7.40m market cap, or US$7.83m).
공고 • Nov 14All Patients Completed AcuCort's Phase IV Study ZEQ001AcuCort's Phase IV study, ZEQ001, began in late January 2024. This study enrolled 50 patients, and the last participant has now completed it. The study findings are intended to be published in scientific journals, providing key support for AcuCort's upcoming launch initiatives. A key objective of the study, an open, non-randomised, low-intervention study, is to obtain scientific data from patients who previously used tablets but, in the study, are using Zeqmelit® instead. The study will answer essential questions, such as whether patients feel confident with Zeqmelit®, what the experience of using the medication is like, and whether they carry it with them. The study results will be published in scientific journals, thereby providing crucial support for the launch of Zeqmelit® in selected markets.
공고 • Oct 24AcuCort AB (publ) to Report Q3, 2024 Results on Nov 22, 2024AcuCort AB (publ) announced that they will report Q3, 2024 results on Nov 22, 2024
공고 • Sep 03Acucort AB (Publ) Announces Launch of Zeqmelit®? Initiated - Now Available At PharmaciesAcuCort has previously announced that the market launch of Zeqmelit®? would begin in early September. In line with this plan, Zeqmelit®? is available at Swedish pharmacies starting on September 2nd. The product will soon also be available at pharmacies in Norway and Finland. The launch is proceeding exactly as planned, and have thus achieved yet another important milestone. Physicians can prescribe Zeqmelit®?, and the product is now available at Swedish pharmacies. It will soon also be available at hospitals in Norway and Finland.
공고 • Jul 25AcuCort AB (publ) to Report First Half, 2024 Results on Aug 23, 2024AcuCort AB (publ) announced that they will report first half, 2024 results on Aug 23, 2024
Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Monica Wallter was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Oct 12AcuCort AB (publ) to Report Q3, 2023 Results on Nov 10, 2023AcuCort AB (publ) announced that they will report Q3, 2023 results on Nov 10, 2023
공고 • Jul 13AcuCort AB (publ) to Report Q2, 2023 Results on Aug 11, 2023AcuCort AB (publ) announced that they will report Q2, 2023 results on Aug 11, 2023